What is included in this Sample?
- * Market Segmentation
- * Key Findings
- * Research Scope
- * Table of Content
- * Report Structure
- * Report Methodology
Download FREE Sample Report
Ursodeoxycholic Acid Market Size, Share, Growth and Industry Analysis By Type (Synthetic UDCA, Extraction UDCA), By Application (Drugs, Health Care Products), Regional Insights and Forecast From 2026 To 2035
Trending Insights
Global Leaders in Strategy and Innovation Rely on Our Expertise to Seize Growth Opportunities
Our Research is the Cornerstone of 1000 Firms to Stay in the Lead
1000 Top Companies Partner with Us to Explore Fresh Revenue Channels
Ursodeoxycholic Acid Market Overview
In 2026, the global ursodeoxycholic acid market is estimated at USD 1.11 Billion. With consistent expansion, the market is projected to attain USD 1.63 Billion by 2035. The market is forecast to grow at a CAGR of 4.3% over the period from 2026 to 2035.
I need the full data tables, segment breakdown, and competitive landscape for detailed regional analysis and revenue estimates.
Download Free SampleThe ursodeoxycholic acid market is supported by established pharmaceutical demand for bile-acid therapies used in hepatobiliary disorders and gallstone management. Synthetic UDCA accounts for an estimated 72% of market supply because controlled synthesis enables pharmaceutical-grade purity, scalable production, traceability, and regulatory compliance. Drugs represent approximately 88% of application demand, reflecting UDCA’s established therapeutic role. Manufacturers increasingly focus on integrated bile sourcing, synthetic conversion, purification, regulatory filings, and sustainable production. Leading producers operate GMP manufacturing networks spanning Europe and Asia, while investments in India are increasing global API availability and strengthening supply-chain resilience for pharmaceutical customers requiring consistent ursodeoxycholic acid quality.
The USA ursodeoxycholic acid market is primarily pharmaceutical and supported by established use of prescription UDCA formulations for hepatobiliary treatment. Pharmaceutical manufacturers depend on regulated API supply chains, validated manufacturing processes, impurity control, documentation, and reliable international sourcing. Competition among API suppliers is influenced by regulatory filing support, GMP compliance, production continuity, quality consistency, and manufacturing traceability. American pharmaceutical companies source UDCA from established international manufacturing networks in Europe and Asia. Demand is also influenced by generic drug availability and continued clinical use of bile-acid therapies. Suppliers increasingly emphasize vertically integrated manufacturing, secure raw-material sourcing, process efficiency, and regulatory documentation to support pharmaceutical customers.
KEY FINDINGS
- Type leadership: Synthetic UDCA holds approximately 72% market share, supported by scalable pharmaceutical production, controlled purity, regulatory compliance, and dependable commercial supply.
- Application leadership: Drugs account for approximately 88% market share, driven by established therapeutic use in hepatobiliary disorders, prescription formulations, and generic medicine availability.
- Key company landscape: Mitsubishi Tanabe Pharma and ICE strengthen competitive positioning through established UDCA expertise, regulated pharmaceutical supply, manufacturing capabilities, and international market presence.
- Fastest growing region: Asia Pacific holds approximately 39% market share, supported by API manufacturing expansion, pharmaceutical production, healthcare access, and increasing regional supply capabilities.
- Key trends: Integrated UDCA manufacturing is expanding, while one major Indian capacity project increased raw UDCA production capability by 120 metric tons annually.
LATEST TRENDS
Improvement of Liver Health After Administration of UDCA Therapy to Increase Market Growth
The ursodeoxycholic acid market is moving toward integrated manufacturing, expanded Asian production, stronger supply traceability, process optimization, and broader pharmaceutical regulatory coverage. Manufacturers increasingly seek control over the complete production chain, from bile-derived starting materials through chemical conversion, purification, quality testing, and finished pharmaceutical API. Synthetic UDCA remains the dominant type with approximately 72% share because pharmaceutical manufacturers require consistent purity, scalable manufacturing, controlled impurities, and documented regulatory compliance. Modern synthetic processes commonly begin with cholic acid obtained from controlled bile sources before multiple chemical transformation and purification stages produce pharmaceutical-grade UDCA.
Capacity expansion is becoming a major market trend. ICE expanded its Indian manufacturing operation with a dedicated facility capable of increasing raw UDCA output by 120 metric tons annually. The project incorporates advanced processing technology and greater automation to strengthen efficiency and supply availability. Another important trend is geographic consolidation. PharmaZell operations are concentrating UDCA manufacturing at an integrated Indian production platform, connecting bile sourcing with API manufacturing. Regulatory diversification is also increasing as manufacturers maintain filings across major pharmaceutical jurisdictions. Companies increasingly compete through secure sourcing, environmental management, regulatory support, manufacturing efficiency, and reliable pharmaceutical-grade supply rather than solely through production volume.
Ursodeoxycholic Acid Market Segmentation
By Type
Based on Type the global market can be categorized in to Synthetic UDCA and Extraction UDCA.
- Synthetic UDCA: Synthetic UDCA represents approximately 72% of the ursodeoxycholic acid market, making it the leading type segment. Commercial pharmaceutical production generally involves conversion of suitable bile-acid starting materials through controlled chemical processing, followed by purification, crystallization, drying, milling, and quality testing. Synthetic manufacturing enables producers to achieve consistent pharmaceutical specifications and establish validated processes for regulated markets. Major producers maintain specialized facilities with reactors, filtration systems, centrifuges, dryers, mills, and analytical laboratories. International manufacturers increasingly integrate starting-material sourcing with final API production to strengthen traceability and supply continuity. Synthetic UDCA also supports regulatory documentation required by pharmaceutical companies manufacturing prescription and generic products.
- Extraction UDCA: Extraction UDCA accounts for approximately 28% of the market. This segment is associated with biologically sourced bile-acid materials and extraction-based processing routes. Historically, animal bile represented an important source for ursodeoxycholic acid and related bile-acid intermediates. Modern pharmaceutical supply chains increasingly emphasize traceability, animal-origin controls, responsible sourcing, and purification because biological starting materials can introduce greater variability than standardized synthetic processing. Extraction remains relevant within integrated bile-acid production networks where manufacturers possess established sourcing relationships and purification expertise. Manufacturers handling animal-derived materials must control collection, storage, transportation, contamination, and species traceability.
By Application
Based on Application the global market can be categorized in to Drugs and Health Care Products.
- Drugs: Drugs represent approximately 88% of ursodeoxycholic acid market demand, establishing pharmaceutical applications as the dominant segment. UDCA is incorporated into prescription medicines used for selected liver, bile-duct, and gallbladder conditions. Commercial dosage forms include tablets, capsules, and oral suspensions, providing flexibility for different patient populations and treatment requirements. Several pharmaceutical markets offer 250 mg capsule formulations, while additional strengths include 100 mg, 200 mg, 300 mg, 450 mg, and 500 mg products. Pharmaceutical manufacturers require API suppliers with validated production systems, appropriate regulatory filings, impurity controls, and GMP compliance. Generic medicine availability supports broader sourcing from qualified UDCA manufacturers. Demand also benefits from established physician familiarity with bile-acid therapy. API suppliers increasingly differentiate through regulatory support, dependable delivery, integrated manufacturing, and production capacity capable of serving multiple finished-dose customers.
- Health Care Products: Health Care Products account for approximately 12% of the ursodeoxycholic acid market. This category includes selected wellness, nutraceutical, and specialized non-prescription formulations containing UDCA or related bile-acid ingredients where permitted by local regulations. Demand remains considerably smaller than pharmaceutical use because UDCA is regulated as a medicinal active ingredient across many major markets. South Korean product portfolios demonstrate broader consumer familiarity with bile-acid ingredients, including formulations positioned around digestive and liver-related health. Manufacturers participating in this segment emphasize ingredient quality, formulation compatibility, dosage control, and regulatory compliance. Opportunities exist where healthcare-product regulations permit bile-acid inclusion, particularly in Asian markets with established consumer awareness. However, regulatory classifications differ substantially between countries, requiring manufacturers to evaluate allowable claims, ingredient status, dosage restrictions, and distribution channels before launching health-oriented products.
MARKET DYNAMICS
Driving Factor
Growing pharmaceutical demand for established hepatobiliary therapies.
The principal ursodeoxycholic acid market driver is sustained pharmaceutical utilization in liver and biliary treatment. UDCA is an established bile acid used in medicines addressing conditions involving impaired bile flow and selected gallstone-related disorders. Pharmaceutical applications represent approximately 88% of market demand, demonstrating the importance of prescription and generic medicine production. Multiple formulations are commercially available, including 100 mg, 200 mg, 250 mg, 300 mg, 450 mg, and 500 mg presentations depending on manufacturer and market. Pharmaceutical companies require consistent API availability because UDCA medicines are used in continuing treatment regimens. Generic competition further broadens sourcing requirements because multiple finished-dose manufacturers need qualified API suppliers. Increasing healthcare access across Asia Pacific and emerging economies also creates opportunities for regulated manufacturers capable of providing pharmaceutical-grade UDCA with suitable regulatory documentation and dependable supply continuity.
Driver Impact Analysis*
| Market Drivers | CAGR Impact | 2026–2028 | 2029–2031 | 2032–2035 |
|---|---|---|---|---|
| Increasing prevalence and diagnosis of hepatobiliary and cholestatic disorders | +1.85% | High | High | High |
| Rising demand for ursodeoxycholic acid in prescription and generic pharmaceutical formulations | +1.35% | High | High | High |
| Growing pharmaceutical-grade UDCA manufacturing capacity across Asia Pacific | +0.95% | Medium | High | High |
| Expansion of healthcare access and hepatobiliary treatments across emerging economies | +0.65% | Medium | Medium | High |
| Increasing adoption of advanced synthetic UDCA production and purification technologies | +0.45% | Low | Medium | Medium |
| Others | +0.30% | Low | Low | Low |
Restraining Factor
Dependence on specialized raw-material sourcing and complex pharmaceutical manufacturing.
UDCA production involves specialized bile-acid chemistry and tightly controlled pharmaceutical processing. Conventional synthetic manufacturing commonly uses cholic acid derived from animal bile as a starting material, making traceability and responsible sourcing important supply considerations. Leading integrated producers collect or source bile materials through international networks before converting cholic acid into pharmaceutical-grade UDCA. Manufacturers must maintain controls covering animal origin, purification, contamination, process consistency, and regulatory documentation. These requirements limit the number of companies capable of supplying major regulated pharmaceutical markets. Synthetic conversion also requires multiple chemical processing and purification stages, increasing technical complexity. Environmental requirements involving solvents, wastewater, and process residues add additional operating considerations. Pharmaceutical customers consequently evaluate suppliers on GMP history, impurity profiles, regulatory filings, traceability, and supply resilience, creating barriers for new manufacturers seeking rapid entry into regulated UDCA markets.
Restraint Impact Analysis*
| Market Restraints | CAGR Impact | 2026–2028 | 2029–2031 | 2032–2035 |
|---|---|---|---|---|
| Dependence on specialized bile-derived raw materials and controlled sourcing networks | -0.55% | High | High | Medium |
| Stringent pharmaceutical quality, GMP compliance, and animal-origin traceability requirements | -0.40% | High | Medium | Medium |
| Complex manufacturing processes and stringent impurity-control requirements for pharmaceutical-grade UDCA | -0.20% | Medium | Medium | Low |
| Others | -0.10% | Low | Low | Low |
Expansion of integrated pharmaceutical-grade UDCA manufacturing in Asia Pacific.
Expansion of integrated pharmaceutical-grade UDCA manufacturing in Asia Pacific.
Opportunity
Asia Pacific offers substantial opportunities as API manufacturers expand capacity, integrate raw-material sourcing, and strengthen compliance with international pharmaceutical standards. The region accounts for an estimated 39% of global ursodeoxycholic acid market activity. India is becoming particularly important for UDCA production. A dedicated Indian manufacturing facility added capability for 120 metric tons of raw UDCA annually, illustrating the scale of new regional investment. PharmaZell is also consolidating UDCA manufacturing at its Vizag operation, creating an integrated production platform extending from bile sourcing to API manufacturing. These investments can strengthen supply security for pharmaceutical customers in North America, Europe, and Asia. Opportunities also exist in high-purity synthesis, process intensification, environmental improvements, generic drug supply, regulatory filing support, veterinary formulations, and healthcare products. Manufacturers capable of combining competitive production with global regulatory standards can address diversified international demand.
Maintaining quality consistency, regulatory compliance, and traceability across global supply chains.
Challenge
Pharmaceutical-grade ursodeoxycholic acid must satisfy demanding purity, impurity, documentation, and manufacturing requirements. Companies operating internationally may require drug master files, certificates of suitability, GMP certifications, and jurisdiction-specific API registrations. One established European supplier maintains regulatory documentation covering the European Union, United States, Canada, Brazil, and China, illustrating the extensive compliance infrastructure required for global commercialization. Manufacturers must also trace animal-derived starting materials and verify that sourcing practices comply with pharmaceutical quality expectations. Any inconsistency in starting materials can affect downstream purification requirements and production efficiency. Global supply networks introduce additional challenges involving transportation, inventory planning, supplier qualification, regulatory inspections, and geopolitical disruptions. Companies therefore need multiple sourcing relationships, robust analytical testing, validated manufacturing processes, and sufficient capacity. Maintaining these capabilities while controlling production costs remains an important competitive challenge.
-
Download Free Sample to learn more about this report
Ursodeoxycholic Acid Market Regional Insights
-
North America
North America accounts for approximately 20% of global ursodeoxycholic acid market activity. The United States represents the dominant regional pharmaceutical market for UDCA-containing prescription products. Drugs account for approximately 93% of regional application demand because medicinal use dominates UDCA consumption. Synthetic UDCA represents approximately 78% of regional supply requirements due to strict pharmaceutical quality and regulatory expectations. API suppliers serving the region commonly maintain United States drug master files and supporting regulatory documentation. Demand emphasizes GMP manufacturing, supply continuity, validated impurity control, and reliable international sourcing.
-
Europe
Europe represents approximately 29% of the global ursodeoxycholic acid market. Drugs account for approximately 91% of European UDCA demand, reflecting established prescription utilization. Synthetic UDCA represents approximately 74% of regional market activity. Italy and Germany maintain important UDCA API manufacturing and pharmaceutical supply capabilities. Multiple 250 mg, 300 mg, 450 mg, and 500 mg finished-dose formulations are available across European pharmaceutical markets. Regulatory compliance, certificates of suitability, GMP manufacturing, and animal-origin traceability strongly influence supplier selection. Europe contains several important UDCA companies, including ICE, Dipharma Francis, Erregierre, PharmaZell, and Grindeks. Established European producers possess extensive experience in bile-acid chemistry, purification, regulatory documentation, and international API supply.
-
Asia Pacific
Asia Pacific leads the global ursodeoxycholic acid market with approximately 39% share. Synthetic UDCA accounts for approximately 69% of regional market activity. Drugs represent approximately 84% of regional applications, while healthcare products account for approximately 16%. India, China, Japan, and South Korea are important manufacturing and consumption markets. Indian production investments are increasing global UDCA supply and strengthening vertically integrated pharmaceutical manufacturing. One dedicated capacity expansion added capability for 120 metric tons of raw UDCA annually. Asia Pacific combines expanding pharmaceutical manufacturing with established bile-acid medicine consumption. India is strengthening its position through integrated API manufacturing and international regulatory compliance. China contributes chemical and biotechnology production, while Japan maintains established pharmaceutical demand and specialized bile-acid manufacturing expertise.
-
Middle East & Africa
Middle East & Africa account for approximately 6% of global ursodeoxycholic acid market demand. Drugs represent approximately 90% of regional applications because prescription pharmaceuticals dominate UDCA consumption. Synthetic UDCA accounts for approximately 75% of regional supply. Saudi Arabia, UAE, South Africa, Egypt, and other pharmaceutical markets support imported UDCA formulations and APIs. Generic medicine distribution provides opportunities for internationally qualified API and finished-dose manufacturers. Regional demand depends strongly on healthcare access, pharmaceutical imports, regulatory registration, and hospital availability. The Middle East increasingly emphasizes pharmaceutical localization and medicine security, potentially creating opportunities for UDCA formulation partnerships. African markets remain more dependent on imported finished medicines and APIs.
-
Rest of the World
Rest of the World represents approximately 6% of global ursodeoxycholic acid market activity. Latin America constitutes an important portion through Brazil, Mexico, Argentina, Colombia, and neighboring pharmaceutical markets. Drugs represent approximately 89% of application demand. Synthetic UDCA accounts for approximately 73% of supply. Brazil maintains specific regulatory requirements for pharmaceutical APIs, encouraging qualified manufacturers to secure local API documentation. Generic pharmaceutical expansion and improving healthcare access support broader availability of hepatobiliary medicines. Brazil is particularly important because pharmaceutical API manufacturers require appropriate regulatory documentation to participate effectively in the market. Dipharma obtained Brazilian regulatory recognition for its ursodeoxycholic acid API, supporting stronger market access.
KEY INDUSTRY PLAYERS
Leading Players adopt Acquisition Strategies to Stay Competitive
The ursodeoxycholic acid market includes specialized bile-acid manufacturers, pharmaceutical API companies, and finished-dose producers. Mitsubishi Tanabe Pharma, ICE, PharmaZell, Dipharma Francis, Grindeks, Daewoong Chemical, Erregierre, Abil Chempharma, Zhongshan belling, Arcelor Chemicals, and Biotavia Labs participate across different stages of the value chain. Competitive strategies include integrated raw-material sourcing, manufacturing capacity expansion, regulatory approvals, geographic diversification, process optimization, and finished-formulation development. ICE maintains a broad international bile-acid network, while PharmaZell is expanding integrated production in India. European manufacturers emphasize regulatory quality and synthesis expertise. Asian suppliers increasingly compete through manufacturing scale, process technology, and growing international pharmaceutical relationships.
Top 2 companies with highest market share
- Mitsubishi Tanabe Pharma: Holds an estimated 15.2% share through established pharmaceutical expertise, UDCA presence, and Asian market coverage.
- ICE: Holds an estimated 12.6% share through integrated bile sourcing, global manufacturing, regulatory support, and UDCA specialization.
LIST OF TOP URSODEOXYCHOLIC ACID COMPANIES
- Mitsubishi Tanabe Pharma
- Erregierre
- ICE
- Grindeks
- Abil Chempharma
- Arcelor Chemicals
- Biotavia Labs
- Zhongshan belling
- Dipharma Francis
- PharmaZell GmbH
- Daewoong Chemical
Market Leadership Matrix: Global Ursodeoxycholic Acid Market
| 2×2 Matrix View | Low to Medium Business Strength | High Business Strength |
|---|---|---|
| High Future Growth Potential | Growth Challengers: • Dipharma Francis • Grindeks • Daewoong Chemical |
Leaders: • ICE • PharmaZell GmbH |
| Low to Medium Future Growth Potential | Emerging / Selective Participants: • Abil Chempharma • Arcelor Chemicals • Biotavia Labs • Zhongshan belling |
Established / Specialized Players: • Mitsubishi Tanabe Pharma • Erregierre |
LEADER INSIGHTS
- PharmaZell GmbH / Axplora: Martin Meeson, Chief Executive Officer of Axplora, said the consolidation of UDCA manufacturing at the PharmaZell Vizag site is intended to create a more scalable and resilient supply platform aligned with evolving customer needs. His comments indicate that growing global UDCA demand, supply-chain reliability, integrated manufacturing, and capacity expansion are central to the company’s long-term market strategy. (Published: June 10, 2026 | Source: Axplora official UDCA manufacturing announcement)
- Daewoong Chemical / Daewoong group: Chang-jae Lee and Seongsoo Park, Chief Executive Officers of Daewoong Pharmaceutical, emphasized continued growth through research, innovation, global competitiveness, and international expansion. Their outlook highlights increasing investment in R&D, sustainable pharmaceutical manufacturing, and broader global market participation, supporting the group’s long-term positioning across APIs and healthcare products, including its established UDCA activities. (Published: 2025 | Source: Daewoong Pharmaceutical 2025 Sustainability Report)
- Mitsubishi Tanabe Pharma: Akihiro Tsujimura, Representative Director, President & Chief Executive Officer at the time of the announcement, oversaw the company’s transition under Bain Capital with a strategy focused on accelerating sustainable growth, strengthening R&D capabilities, expanding external collaboration, and increasing global presence. The initiative reflects continued emphasis on pharmaceutical innovation and international market expansion as the company repositioned for its next growth phase. (Published: July 1, 2025 | Source: Mitsubishi Tanabe Pharma official announcement)
Investment Analysis and Opportunities
Investment activity increasingly targets production capacity, vertical integration, pharmaceutical compliance, supply security, and sustainable bile-acid manufacturing. Asia Pacific represents approximately 39% of market activity and offers substantial opportunities for capacity expansion. ICE commissioned a dedicated Indian facility capable of increasing raw UDCA production by 120 metric tons annually, strengthening its integrated global manufacturing network. PharmaZell is similarly consolidating UDCA manufacturing at Vizag, creating a platform connecting bile sourcing with final API production. Further opportunities exist in synthetic process optimization, biotechnology-based conversion, solvent recovery, wastewater reduction, automated manufacturing, analytical testing, and regulatory documentation. Generic drug manufacturers also create opportunities for qualified API suppliers entering additional regulated markets.
New Product Development
New product development is focusing on optimized UDCA formulations, dosage flexibility, higher-purity APIs, efficient synthetic routes, and specialized healthcare applications. Pharmaceutical manufacturers offer UDCA across several oral strengths, with 250 mg remaining a widely established capsule presentation. Veterinary development is emerging as another niche opportunity. Daewoong Pet announced a 50 mg veterinary UDCA tablet in 2026 to complement its existing 200 mg product, improving dosing consistency for companion animals requiring long-term hepatobiliary management. API manufacturers are simultaneously improving synthesis and purification processes to strengthen consistency and reduce manufacturing complexity. Future innovation may include enhanced formulations, improved oral delivery, sustainable bile sourcing, biotechnology-assisted production, and manufacturing processes designed to reduce solvent consumption and environmental impact.
Five Recent Developments
- July 2025 – ICE, New Indian manufacturing block expands dedicated chicken-bile UDCA production capability.
ICE inaugurated a dedicated manufacturing facility, expanding raw UDCA capacity by 120 metric tons annually while introducing advanced equipment, automation, and integrated pharmaceutical processing capabilities.
- June 2026 – PharmaZell GmbH, Vizag consolidation strengthens integrated global ursodeoxycholic acid manufacturing supply platform.
PharmaZell consolidated UDCA manufacturing at Vizag, integrating bile sourcing with API production to improve scalable capacity, traceability, responsiveness, operational efficiency, and global supply reliability.
- February 2026 – Daewoong Chemical, Low-dose veterinary UDCA formulation expands specialized hepatobiliary treatment options.
Daewoong expanded its UDCA portfolio with a 50 mg veterinary formulation, improving dosage precision, reducing compounding requirements, and supporting long-term companion-animal hepatobiliary disease management.
- October 2025 – Grindeks, Updated 250 mg UDCA capsule documentation strengthens regulated European availability.
Grindeks maintained regulated 250 mg ursodeoxycholic acid capsule availability with updated pharmaceutical documentation, supporting prescription supply, standardized dosing, regulatory compliance, and European hepatobiliary treatment access.
- October 2025 – Dipharma Francis, Expanded regulatory positioning strengthens international UDCA active pharmaceutical ingredient accessibility.
Dipharma strengthened UDCA regulatory positioning through multi-jurisdiction documentation, supporting pharmaceutical customers with compliant API supply, quality assurance, international registrations, and established Italian manufacturing capabilities.
Report Coverage
The ursodeoxycholic acid market report evaluates production technologies, pharmaceutical applications, regional demand, competitive positioning, manufacturing investments, regulatory developments, and product innovation. Type coverage includes Synthetic UDCA and Extraction UDCA, with Synthetic UDCA representing approximately 72% of market activity. Application coverage includes Drugs and Health Care Products, with Drugs accounting for approximately 88%. Regional analysis covers North America, Europe, Asia Pacific, Middle East & Africa, and Rest of the World, with shares totaling exactly 100%. The report also evaluates bile sourcing, pharmaceutical synthesis, purification, GMP manufacturing, regulatory documentation, capacity expansion, supply-chain integration, generic medicines, veterinary applications, competitive strategies, and emerging manufacturing opportunities.
| Attributes | Details |
|---|---|
|
Market Size Value In |
US$ 1.11 Billion in 2026 |
|
Market Size Value By |
US$ 1.63 Billion by 2035 |
|
Growth Rate |
CAGR of 4.3% from 2026 to 2035 |
|
Forecast Period |
2026 - 2035 |
|
Base Year |
2025 |
|
Historical Data Available |
Yes |
|
Regional Scope |
Global |
|
Segments Covered |
|
|
By Types
|
|
|
By End Users
|
FAQs
The global Ursodeoxycholic Acid Market is expected to reach USD 1.63 billion by 2035.
The Ursodeoxycholic Acid Market is expected to exhibit a CAGR of 4.3% by 2035.
UDCA therapy is found out to be very effective in treating medical conditions like cystic fibrosis, and, primary biliary cirrhosis. Hence, the number of people opting for this treatment has significantly increased.
Mitsubishi Tanabe Pharma, Erregierre, ICE, Grindeks, Abil Chempharma, Arcelor Chemicals, Biotavia Labs, Zhongshan belling, Dipharma Francis, PharmaZell GmbH, Daewoong Chemical are the top companies operating in the ursodeoxycholic acid market.
